SCHEMBL22979466

SCHEMBL22979466

O=C1NCCNCC1Nc1nc2cccc(Cl)c2c2nc(-c3ccc(F)cc3)nn12

nearest known ligand 0.37

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 7/20 0.37
DGAT2 Q96PD7 1/20 0.35
ADORA2A P29274 4/20 0.34
ADORA1 P30542 4/20 0.34
MAPT P10636 3/20 0.34
XDH P47989 1/20 0.34
FPR2 P25090 1/20 0.32
SCN9A Q15858 1/20 0.32
PRKCI P41743 1/20 0.32
GRIA1 P42261 1/20 0.32
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29645722 1.00 ADORA3 (0.37) ADORA3DGAT2ADORA2AADORA1MAPT
SCHEMBL29645934 1.00 ADORA3 (0.37) ADORA3DGAT2ADORA2AADORA1MAPT
SCHEMBL29645526 1.00 ADORA3 (0.37) ADORA3DGAT2ADORA2AADORA1MAPT
SCHEMBL22980999 1.00 ADORA3 (0.37) ADORA3DGAT2ADORA2AADORA1MAPT
SCHEMBL22988284 0.92 ADORA3 (0.37) ADORA3DGAT2ADORA2AADORA1MAPT
SCHEMBL29645978 0.92 ADORA3 (0.37) ADORA3DGAT2ADORA2AADORA1MAPT
SCHEMBL22988343 0.90 XDH (0.34) ADORA3ADORA2AADORA1MAPTXDH
SCHEMBL22979383 0.90 XDH (0.34) ADORA3ADORA2AADORA1MAPTXDH
SCHEMBL29645550 0.90 XDH (0.34) ADORA3ADORA2AADORA1MAPTXDH
SCHEMBL22979905 0.89 MAPT (0.39) ADORA3ADORA2AADORA1MAPTXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US claimed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP claimed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO claimed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 ADORA3 34/4885DGAT2 4129/4885ADORA2A 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.